Emergent BioSolutions Inc. (EBS) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Emergent BioSolutions reported revenue of $742.9M, down 28.8% from $1.04B the year before. Net income was $52.6M (a 7.1% net margin), or $0.93 per diluted share. Gross margin was 56.1% and operating margin was 13.5%. Operating activities generated $170.6M of cash, leaving $156.8M of free cash flow. At fiscal year end, Emergent BioSolutions held $1.32B in total assets against $796.0M in total liabilities, including $205.4M of cash and equivalents.
Open the full interactive Emergent BioSolutions financials → Quarterly statements, key ratios, valuation history and price charts.
Emergent BioSolutions Key Stats
| Share Price | $6.91 |
|---|---|
| Market Cap | $356.6M |
| P/E Ratio | 7.4 |
| Revenue YoY Growth | -28.8% |
| 52-Week Range | $4.45 – $13.90 |
| Shares Outstanding | 51.6 million (basic, 2026 Q2) |
Emergent BioSolutions Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $1.56B | $1.79B | $1.12B | $1.05B | $1.04B | $742.9M |
| Cost of Goods Sold | $524.0M | $382.0M | $693.7M | $705.4M | $185.9M | $326.2M |
| Gross Profit | $1.03B | $1.41B | $385.8M | $317.6M | $857.7M | $416.7M |
| Operating Income | $433.8M | $352.6M | -$172.7M | -$726.4M | -$108.7M | $100.1M |
| Pre-Tax Income | $407.2M | $314.4M | -$221.7M | -$731.2M | -$142.9M | $82.8M |
| Income Tax | $102.1M | $83.5M | $2.1M | $29.3M | $47.7M | $30.2M |
| Net Income | $305.1M | $230.9M | -$223.8M | -$760.5M | -$190.6M | $52.6M |
| Diluted EPS | $5.67 | $4.27 | -$4.47 | -$14.85 | -$3.60 | $0.93 |
Emergent BioSolutions Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $231.1M | $148.7M | $156.1M | $234.3M |
| Net Income | $51.2M | -$54.6M | $6.8M | -$180.2M |
| Diluted EPS | $0.91 | -$0.96 | $0.07 | -$3.49 |
Emergent BioSolutions Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $621.3M | $576.1M | $642.6M | $111.7M | $99.5M | $205.4M |
| Current Assets | $1.20B | $1.27B | $1.21B | $679.5M | $598.7M | $662.5M |
| Total Assets | $2.88B | $2.96B | $3.17B | $1.82B | $1.39B | $1.32B |
| Current Liabilities | $384.5M | $373.8M | $1.23B | $651.3M | $162.4M | $132.2M |
| Total Long-Term Debt | $874.8M | $841.0M | $1.41B | $860.2M | $700.0M | $589.7M |
| Total Liabilities | $1.44B | $1.34B | $1.78B | $1.17B | $906.9M | $796.0M |
| Shareholders' Equity | $1.45B | $1.62B | $1.38B | $649.3M | $482.8M | $522.6M |
Emergent BioSolutions Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | $536.0M | $321.1M | -$34.1M | -$206.3M | $58.7M | $170.6M |
| Cash From Investing | -$151.0M | -$225.0M | -$381.3M | $212.3M | $125.2M | $69.4M |
| Cash From Financing | $69.5M | -$141.0M | $481.2M | -$535.7M | -$190.0M | -$136.6M |
| Free Cash Flow | $395.0M | $96.1M | -$149.9M | -$257.9M | $35.8M | $156.8M |
Figures from Emergent BioSolutions' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Emergent BioSolutions financials page for every line item.
Emergent BioSolutions Company Profile
| Ticker | EBS |
|---|---|
| Exchange | NYSE |
| Industry | Pharmaceutical Preparations |
| Headquarters | Gaithersburg, Maryland |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Accelerated filer |
| SEC CIK | 0001367644 |
Frequently Asked Questions
What was Emergent BioSolutions' revenue in fiscal 2025?
Emergent BioSolutions (EBS) reported revenue of $742.9M for fiscal 2025.
What is Emergent BioSolutions' annual revenue history?
Emergent BioSolutions' annual revenue by fiscal year: 2020: $1.56B; 2021: $1.79B; 2022: $1.12B; 2023: $1.05B; 2024: $1.04B; 2025: $742.9M.
What was Emergent BioSolutions' net income in fiscal 2025?
Emergent BioSolutions reported net income of $52.6M for fiscal 2025.
What was Emergent BioSolutions' earnings per share (EPS) in fiscal 2025?
Emergent BioSolutions' diluted EPS was $0.93 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Emergent BioSolutions generate in fiscal 2025?
Emergent BioSolutions generated $156.8M of free cash flow in fiscal 2025.
What was Emergent BioSolutions' revenue last quarter?
In its most recent reported quarter (2026 Q2), Emergent BioSolutions reported revenue of $234.3M.
How much debt does Emergent BioSolutions have?
Emergent BioSolutions reported $589.7M of long-term debt, including the current portion, at the end of fiscal 2025.
How many shares of Emergent BioSolutions are outstanding?
Emergent BioSolutions reported a weighted average of 51.6 million basic shares outstanding in 2026 Q2.
What is Emergent BioSolutions' market cap?
Based on its latest closing price, Emergent BioSolutions (EBS) has a market capitalization of about $356.6M.
When does Emergent BioSolutions' fiscal year end?
Emergent BioSolutions' fiscal year end, as registered with the SEC, is December 31.
Where is Emergent BioSolutions headquartered?
Emergent BioSolutions lists its business address in Gaithersburg, Maryland in its SEC filings.